Abstracts tagged "microbiome and mucosal T cells"

Abstract Number: 402 • 2017 ACR/ARHP Annual Meeting
Alteration of the Intestinal Microbiome in the Preclinical Phase of Experimental Arthritis and the Efficacy of Microbiota Modulation in Established Arthritis in Mice
Rebecca Rogier¹, Heather Evans-Marin², Julia Manasson³, Peter M. van der Kraan⁴, Wim B. van den Berg⁵, Marije I. Koenders⁴, Jose U. Scher⁶ and Shahla Abdollahi-Roodsaz^7,8, ¹Experimental Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, ²Division of Rheumatology, New York University School of Medicine, New York, NY, ³Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁴Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, ⁵Rheumatology Research and Advanced Therapeutics, Radboud University Medical Center, Nijmegen, Netherlands, ⁶New York University School of Medicine, New York, NY, ⁷Department of Medicine, Division of Rheumatoogy, New York University School of Medicine, New York, NY, ⁸Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands
Background/Purpose: The composition of intestinal microbiota is perturbed in patients with new-onset and chronic rheumatoid arthritis (RA). However, it is not known whether the changes…
Abstract Number: 1202 • 2016 ACR/ARHP Annual Meeting
Characteristic Compositional and Functional Alteration of Gut Microbiota in Patients with Behcet’s Disease
Noboru Suzuki¹, Jun Shimizu² and Takao Kubota³, ¹Department of Immunology and medicine, St. Marianna University School of Medicine, Kawasaki-shi, 216-8511, Japan, ²Department of Immunology and Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ³The Japan Self Defense Forces Central Hospital, Tokyo, Japan
Background/Purpose: We have presented evidence that the frequency of helper T (Th)17 cells increased and the cells had already been activated in vivo in patients…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].